ADI 100
Alternative Names: ADI™-100Latest Information Update: 30 May 2024
At a glance
- Originator ADiTxT Therapeutics
- Developer Adimune; ADiTxT Therapeutics
- Class Antihyperglycaemics; Antipsoriatics; DNA
- Mechanism of Action Apoptosis stimulants; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Psoriasis; Type 1 diabetes mellitus
Most Recent Events
- 30 May 2024 ADiTxT Therapeutics plans a clinical trial for Stiff person syndrome in 2024
- 23 May 2024 ADiTxT Therapeutics submits an IND application to International Review Board and US FDA for a clinical trial in Stiff person syndrome before May 2024
- 18 Aug 2023 Preclinical trials in Type 1 diabetes mellitus in USA, prior to August 2023(unspecified route)